DiappyMed

DiappyMed specializes in personalized digital health solutions aimed at enhancing diabetes management, particularly for Type 1 diabetes patients, through innovative applications that calculate insulin doses and facilitate carbohydrate counting. Founded in 2021 in Clapiers, France, DiappyMed develops digital health solutions for diabetes management. The company has engaged in one funding round, raising EUR 5 million on 23 March 2026, co-led by Ventech and AFI Ventures, with participation from Sofilaro and IRDI Capital Investissement. The founder's history is not detailed, and there are no mentions of subsidiaries or significant pivots in company strategy.

DiappyMed focuses on digital health solutions to assist diabetes patients, primarily through its core products: the EkiYou® application, which personalizes insulin dosing based on various factors, and EkiYou Carbs, a mobile app that simplifies carbohydrate counting. These tools are designed to improve daily management for users diagnosed with diabetes and are available in various European markets. DiappyMed operates on a subscription-based model, particularly for the EkiYou Carbs application, which offers a basic version and a full version at a monthly subscription rate of EUR 6. 99.

Revenue is generated primarily from direct-to-consumer subscriptions and partnerships with healthcare providers who recommend DiappyMed's solutions to their patients. In March 2026, DiappyMed raised EUR 5 million in venture funding aimed at expanding its teams dedicated to training healthcare professionals, enhancing patient support, and advancing research and development. The company plans to launch new products that will further assist diabetes management and is exploring opportunities to enter new markets across Europe by the end of 2026.